Short-term BMI trajectories as a prognostic predictor in patients with pancreatic cancer.
[OBJECTIVE] While numerous studies have examined the association between body mass index (BMI) and cancer prognosis, most have only captured BMI at a single time point.
- 95% CI 1.19-2.41
- HR 1.69
APA
Li C, Zhong Y, et al. (2025). Short-term BMI trajectories as a prognostic predictor in patients with pancreatic cancer.. Frontiers in nutrition, 12, 1680626. https://doi.org/10.3389/fnut.2025.1680626
MLA
Li C, et al.. "Short-term BMI trajectories as a prognostic predictor in patients with pancreatic cancer.." Frontiers in nutrition, vol. 12, 2025, pp. 1680626.
PMID
41710595
Abstract
[OBJECTIVE] While numerous studies have examined the association between body mass index (BMI) and cancer prognosis, most have only captured BMI at a single time point. Whether BMI trajectories are linked to the prognosis of pancreatic cancer remains unclear. This study aimed to investigate the relationship between short-term BMI trajectories and clinical outcomes in patients with pancreatic cancer.
[METHODS] A retrospective study was performed on 200 pancreatic cancer patients who admitted to our hospital from January 1, 2017 to December 31, 2021. BMI 1 (BMI of patients diagnosed with pancreatic cancer 1 year before), BMI 2 (BMI of the patient at diagnosis of pancreatic cancer), BMI 3 (BMI of patients 6 months after diagnosis of pancreatic cancer), BMI 4 (BMI 1-BMI 2), BMI 5 (BMI 3-BMI 2) and BMI 6 (the longitudinal BMI trajectory) were recorded. Clinical-pathological characteristics, oncologic outcomes, progression free survival (PFS) and overall survival (OS) were collected. The prognostic significance was determined by Kaplan-Meier analysis, Cox proportional hazards and restricted cubic spline regression models.
[RESULTS] We found that changes in BMI may be a predictor of pancreatic cancer survival. The results of the multivariate analysis of factors influencing the pancreatic cancer OS showed that BMI 4 ≥1.3 (HR: 1.69, 95% CI: 1.19-2.41, = 0.004), BMI 5 <-0.3 (HR: 3.05, 95% CI: 2.01-4.65, < 0.001) and BMI 6 (patients from normal BMI to low BMI, HR: 2.51, 95% CI: 1.09-5.77, = 0.031; patients from high BMI to normal BMI, HR: 2.01, 95% CI: 1.09-3.70, = 0.025) indicated higher mortality rate.
[CONCLUSION] This study confirms that short-term BMI trajectories before and after diagnosis, as well as early during treatment, are independent prognostic factors for both overall survival and progression-free survival in pancreatic cancer patients. Particular attention should be paid to patients who are normal-weight at diagnosis but transition to a low-BMI category shortly after treatment, as they face the highest mortality risk.
[METHODS] A retrospective study was performed on 200 pancreatic cancer patients who admitted to our hospital from January 1, 2017 to December 31, 2021. BMI 1 (BMI of patients diagnosed with pancreatic cancer 1 year before), BMI 2 (BMI of the patient at diagnosis of pancreatic cancer), BMI 3 (BMI of patients 6 months after diagnosis of pancreatic cancer), BMI 4 (BMI 1-BMI 2), BMI 5 (BMI 3-BMI 2) and BMI 6 (the longitudinal BMI trajectory) were recorded. Clinical-pathological characteristics, oncologic outcomes, progression free survival (PFS) and overall survival (OS) were collected. The prognostic significance was determined by Kaplan-Meier analysis, Cox proportional hazards and restricted cubic spline regression models.
[RESULTS] We found that changes in BMI may be a predictor of pancreatic cancer survival. The results of the multivariate analysis of factors influencing the pancreatic cancer OS showed that BMI 4 ≥1.3 (HR: 1.69, 95% CI: 1.19-2.41, = 0.004), BMI 5 <-0.3 (HR: 3.05, 95% CI: 2.01-4.65, < 0.001) and BMI 6 (patients from normal BMI to low BMI, HR: 2.51, 95% CI: 1.09-5.77, = 0.031; patients from high BMI to normal BMI, HR: 2.01, 95% CI: 1.09-3.70, = 0.025) indicated higher mortality rate.
[CONCLUSION] This study confirms that short-term BMI trajectories before and after diagnosis, as well as early during treatment, are independent prognostic factors for both overall survival and progression-free survival in pancreatic cancer patients. Particular attention should be paid to patients who are normal-weight at diagnosis but transition to a low-BMI category shortly after treatment, as they face the highest mortality risk.
같은 제1저자의 인용 많은 논문 (5)
- Combination therapy for colorectal cancer with anti-PD-L1 and cancer vaccine: A multiscale mathematical model of tumor-immune interactions.
- Concurrent MLL-AF4 infant ALL in monozygotic twins: a case report.
- Adaptive and migration-enhanced tree seed algorithm for multi-threshold CT image segmentation and lung cancer recognition.
- Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
- Interaction Effects Between Tongue-Rolling Behavior and Chronic Stress on Plasma Immune-Inflammatory Indicators, Milk Protein Composition, and Milk Proteome in Dairy Cows.